Results 71 to 80 of about 17,271 (194)
20.500.12530/87858Spironolactone when combined with abiraterone in metastatic castration-resistant prostate cancer (mCRPC) may theoretically exert androgenic properties, thereby compromising the therapeutic effectiveness of abiraterone. Two patients with
Vicente-Valor, Juan +19 more
core +1 more source
Enzalutamide and abiraterone are hormonal treatments that improve survival in metastatic castration‐resistant prostate cancer. Identifying genetic variants associated with the clearance of these drugs may aid in improved dosing and outcomes. We performed
Nadine Norton +12 more
doaj +1 more source
Background: Real-world data on chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone plus prednisone are limited, largely deriving from small retrospective studies.
Giuseppe Procopio +21 more
doaj +1 more source
Quantitation of Cirtuvivint (SM08502) in Human Plasma by LC–MS/MS
ABSTRACT CDC‐like kinases (CLK) and dual‐specificity tyrosine‐regulated kinases (DYRK) are protein kinases involved in various cellular functions, mRNA splicing, and DNA damage repair. CLK/DYRK kinases have been implicated in many disorders such as diabetes, neurodegenerative diseases, and cancer.
Julianne L. Holleran +10 more
wiley +1 more source
HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer
BACKGROUND: A common germline variant in HSD3B1(1245A>C) encodes for a hyperactive 3beta-hydroxysteroid dehydrogenase 1 (3betaHSD1) missense that increases metabolic flux from extragonadal precursor steroids to DHT synthesis in prostate cancer.
Alyamani, Mohammad +19 more
core +1 more source
Improved prostate cancer therapeutics through KinetiSol® enabled amorphous solid dispersions of Abiraterone [PDF]
A majority of anticancer drugs have inherently poor water solubility, which limits their oral bioavailability and therapeutic potential. In Chapter one, the ability of amorphous solid dispersions (ASDs), to improve the dissolution, pharmacokinetics ...
Gala, Urvi Hasmukhlal
core +1 more source
Yasser Rehman1, Jonathan E Rosenberg21Division of Hospital Medicine, UMass Memorial Healthcare, Worcester, MA, USA; 2Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USAAbstract: Prostate cancer is
Rosenberg JE, Rehman Y
core
Comparison of infection risk between enzalutamide and abiraterone in patients with prostate cancer [PDF]
Background Enzalutamide and abiraterone may differ in their immunomodulatory effects, and the prednisone coadministered with abiraterone can be immunosuppressive.
Tse, Gary +9 more
core +1 more source
Introduction. A number of drugs, which improve overall survival and quality of patients’ life, became available for treatment of metastatic castration-resistant prostate cancer (mCRPC).
N. A. Avxentyev +2 more
doaj +1 more source
PURPOSE: Adding ipatasertib to abiraterone and prednisone/prednisolone significantly improved radiographic progression-free survival for patients with metastatic castration-resistant prostate cancer (mCRPC) with PTEN-loss tumours by immunohistochemistry ...
Bracarda, S +29 more
core +1 more source

